title: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.
abstract: We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.
authors.affiliation: The Royal Marsden Hospital, London and Surrey, UK.
authors.forename: Mary
authors.initials: M
authors.lastname: Gleeson
authors.affiliation: Department of Oncology and Clinical Haematology, Austin Health, Heidelberg, Melbourne, Australia.|Eastern Health, Melbourne, Australia.
authors.forename: Eliza A
authors.initials: EA
authors.lastname: Hawkes
authors.affiliation: The Royal Marsden Hospital, London and Surrey, UK.
authors.forename: David
authors.initials: D
authors.lastname: Cunningham
authors.affiliation: Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
authors.forename: Nick
authors.initials: N
authors.lastname: Chadwick
authors.affiliation: Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
authors.forename: Nicholas
authors.initials: N
authors.lastname: Counsell
authors.affiliation: Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
authors.forename: Anthony
authors.initials: A
authors.lastname: Lawrie
authors.affiliation: HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
authors.forename: Andrew
authors.initials: A
authors.lastname: Jack
authors.affiliation: Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
authors.forename: Paul
authors.initials: P
authors.lastname: Smith
authors.affiliation: Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
authors.forename: Paul
authors.initials: P
authors.lastname: Mouncey
authors.affiliation: East Kent Hospitals, Canterbury, UK.
authors.forename: Christopher
authors.initials: C
authors.lastname: Pocock
authors.affiliation: University College London, London, UK.|Mount Vernon Cancer Centre, Northwood, UK.
authors.forename: Kirit M
authors.initials: KM
authors.lastname: Ardeshna
authors.affiliation: The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
authors.forename: John
authors.initials: J
authors.lastname: Radford
authors.affiliation: Nottingham City Hospital, Nottingham, UK.
authors.forename: Andrew
authors.initials: A
authors.lastname: McMillan
authors.affiliation: Western General Hospital, Edinburgh, UK.
authors.forename: John
authors.initials: J
authors.lastname: Davies
authors.affiliation: Torbay Hospital, Torquay, UK.
authors.forename: Deborah
authors.initials: D
authors.lastname: Turner
authors.affiliation: Royal Cornwall Hospital, Truro, UK.
authors.forename: Anton
authors.initials: A
authors.lastname: Kruger
authors.affiliation: Cancer Research UK Centre, Southampton, UK.
authors.forename: Peter W M
authors.initials: PW
authors.lastname: Johnson
authors.affiliation: Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
authors.forename: Joanna
authors.initials: J
authors.lastname: Gambell
authors.affiliation: University College London, London, UK.
authors.forename: David
authors.initials: D
authors.lastname: Linch
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008479:Mediastinal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D064847:Multimodal Imaging; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D016016:Proportional Hazards Models; D000069283:Rituximab; D016896:Treatment Outcome; D047368:Tumor Burden; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: clinical trials; diffuse large B-cell lymphoma; non-Hodgkin lymphoma; primary mediastinal B-cell lymphoma; rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone